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The purpose of this study was to develop the application method of Signal Amplification By 
Reversible Exchange (SABRE) hyperpolarization to a pharmaceutically approved drug 
Letrozole. Letrozole is a drug used to treat breast cancer. It belongs to the family of drugs 
called aromatase inhibitors. Aromatase is the cytochrome P450 enzyme complex, which 
convert androgenic steroids into estrogenic steroids. Around 70% of breast cancer cells are 
sensitive to estrogen (or estrone - a potent endogenous estrogen), which contributes to the 
initiation, promotion and progression of breast cancer. Firstly, this study focused on full 
characterisation of 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile (letrozole) and 
on synthesis and full characterisation of the derivatives that lead up to its structure. Secondly, 
it was essential to develop a quantitative method of detection of all the compounds using 
bench top 1H Nuclear Magnetic Resonance (NMR) spectrometry. Thirdly, the largest part of 
the project was investigating the feasibility to hyperpolarize the compounds, focused mainly 
on letrozole, due to the presence of triazole functional group present in all of them. 
Hyperpolarization is known to lower detection limits, offer quicker and better analysis results, 
and cut costs when compared to regular NMR analysis. Due to the ease of use and the low 
costs, SABRE was the method used to achieve hyperpolarization of the compounds. The 
hyperpolarization of compounds 1,2,4-triazole, 1-methyl-1H-1,2,4-triazole, 1-benzyl-1,2,4-
triazole, 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile, and letrozole were successful, with 
1,2,4-triazole having the highest peak enhancement of -54 following polarization transfer in 
a 65 G field, with letrozole, which is significantly more complex in terms of its molecular 
architecture, having the lowest peak enhancement of -7. Only the biggest peak enhancements 
have been recorded for each molecule. The fact that SABRE hyperpolarization produced 
negative signal improvement in the 1H NMR spectrum of letrozole suggests, that the clinically 
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approved drug could be hyperpolarized, and potentially used in molecular imaging as a breast 




Abbreviation and acronyms: 
AI(s) – Aromatase inhibitor(s) 
cm-1 – Wavenumber 
ERBB2 – Erb-B2 Receptor Tyrosine Kinase 2 
ER – Estrogen Receptor 
ER+ – Estrogen Receptor-Positive 
fo - Larmor frequency 
GC-MS – Gas Chromatography-Mass Spectrometry 
Hz – Hertz 
HR – Hormone Receptor 
IR – Infrared 
Mz – Longitudinal magnetisation 
MP – Melting point 
mL – Millilitres 
mmol or mM – Millimole 
NMR – Nuclear Magnetic Resonance 
ppm – parts per million  
RRT – Relative retention time 
S, M, W, B – Infrared signal strengths; Strong, Medium, Weak, Broad 
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1.   Introduction 
 1.1 Breast cancer 
Cancer is one of the leading causes of death worldwide with a fatality rate of 165,000 deaths 
every year in the UK.1,2 In women, according to new cases, the most common cancer is breast 
cancer.3 70-80% of cases in patients with the early-stage non-metastatic disease lead to a 
good prognosis and a high survival rate. Advanced breast cancer with distant organ 
metastases is considered incurable with currently available therapies.4 Breast cancer is a 
multifactorial disease and its occurrence is dependent on various factors, such as aging, sex, 
estrogen, gene mutations, family history and unhealthy lifestyle.5,6 The ductal 
hyperproliferation is usually the prime cause of breast tumours, which when undetected, may 
develop into benign tumours or even metastatic carcinomas.7 Recent numbers show, that the 
amount breast cancer cases is 100 times higher in women than that in men.8 
Depending on the absence or presence, of molecular markers for progesterone or estrogen 
receptors (HR) and human epidermal growth factor 2 (ERBB2/HER2), breast cancer is 
categorised into four major subtypes: HR positive/ERBB2 negative (70% of patients), HR and 
ERBB2 positive (15 % of patients), triple-negative (HR and ERBB2 negative, tumours lacking all 
3 standard molecular markers; 10% of patients), and HR negative/ERBB2 positive (ERBB2-
enriched, 5% of patients).9,10 Cells that are sensitive to estrogen contribute to the initiation, 
promotion and progression of breast cancer.11 
Aromatase (such as the cytochrome P450 enzyme complex – CYP19) converts C19 androgenic 
steroids into C18 estrogenic steroids (either directly or by forming testosterone first) as shown 
in Figure 1. Unlike other cytochrome P450 enzymes, this CYP19 hemeprotein has unique 
androgenic specificity.12 The process depicted in Figure 1 is a three-step process, which 
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involves the removal of the C19-methyl group (via two steps of hydroxylation which releases 
formic acid as a by-product) and aromatization of the steroid A-ring by oxidation of the 2β-
hydrogen.13,14 It has been found that the expression of aromatase is highest in or near breast 
tumour sites.15 Over the years, different treatment methods have been invented to help the 
people who are suffering from breast cancer.16 In the past, there were two ways in which 
estrogen-dependent breast cancers may have been interrupted. The first method was using 
selective estrogen receptor modulators (SERMs) like tamoxifen 1 (Table 1), to interfere with 
the binding of estrogen to the tumour’s estrogen receptor (ER). Although recent literature 
describes cases of hormone resistance in breast cancer, a new generation drugs are yet to 
replace tamoxifen in clinical practice.17 The second method was to eliminate or reduce ER 
expression, using fulvestrant 2, a selective estrogen receptor down-regulator (SERD), which 
makes less receptors available for binding, by causing severe receptor conformational 
changes, promoting receptor degradation and downregulation of ER protein level.18,19 In the 
1970s a third method was invented, which targeted aromatase and reduced the amount of 




















Figure 1. Biosynthesis of estriol.21 
12 
 




Estrogens are a group of steroidal compounds that serve as the primary female sex hormones. 
They play an important role in the reproductive, as well as non-reproductive, systems.26 
Estrogens are also associated with the growth and survival of normal and cancerous breast 
epithelial cells by binding to the ER and activating it. In premenopausal women, estrogens are 
primarily produced inside the ovaries and placenta, although a small but significant amount 
of the compounds can also be produced by non-gonadal organs.27 Naturally occurring (or 
endogenous) estrogens which predominate physiologically in females are: estrone (E1), 
estradiol (E2, or 17β-estradiol), and estriol (E3), shown in Figure 1. Each compound is 
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before. E2 is the major product, and the most potent estrogen produced during the 
premenopausal period and E1 having a bigger role postmenopause.27 Estradiol functions as a 
circulating hormone, which acts on target distal estrogen-responsive tissues. For 
postmenopausal women once the ovaries stop producing estrogen and in men, this is no 
longer the case, and the hormone is no longer just an endocrine factor.28 Instead, it acts locally 
(as a paracrine - cell-to-cell communication or intracrine - inside a cell communication) at 
extragonadal sites (such as the breasts) where it is produced.29 During the biosynthesis of 
estrogen, the enzyme responsible for the last step in synthesis is aromatase CYP19.  
 
1.2 Aromatase inhibitors (AIs) 
Aromatase inhibitors (AIs) interfere with the body's ability to convert androstenedione into 
estrogen by suppressing aromatase enzyme activity. All non-steroidal aromatase inhibitors 
possess 3 N heteroatoms, located on 1,2,4-triazole as a common chemical feature.30 These 
AIs bind to the heme iron of the cytochrome P450s with the heteroatom, interfering with 
steroid hydroxylations. The aromatase gene promoter in breast tissue (unlike the ovarian 
aromatase) is sensitive to increments in inflammatory cytokines, which increases with age, 
and with proliferative breast disease and breast cancer. This causes an increase in the activity 
of breast aromatase.30 
There have been three generations of AIs developed over the years (Table 2) with each 
successive generation showing greater suppression of aromatase enzyme activity while also 
showing fewer side effects, making third generation AIs superior to their earlier counterparts. 
Non-steroidal AIs such as letrozole 3 and anastrozole 4 reversibly bind to the aromatase 
enzyme, and steroidal AIs like exemestane 5 do the opposite.31 
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Table 2. Different aromatase inhibitor drug generations, with their recommended dose and 
% of successful aromatase inhibition in vivo achieved at the recommended dose.30 




















































25 mg 98 
15 
 
Compound 6 is considered the first-generation inhibitor or the prototype. It was originally 
used as an antiepileptic agent that was later removed due to side effects. One of those side-
effects was the inhibition of cytochrome P450 (specifically CYP19), which begun the concept 
of using AIs to treat breast cancer. After the discovery of 6, second generation inhibitors have 
been made (7 & 8), with the inhibitory activity being 700 times more potent than the previous 
generation. However, these compounds showed some non-selective inhibitory activity, like 
the reduction of plasma aldosterone, production asymptomatic orthostatic hypotension, and 
increase of plasma levels of androstenedione and testosterone32,33, hence the third 
generation of inhibitors were produced. Inhibitors 3 and 4 have a high % inhibition, with very 
little dose, which makes them primary treatment medicines for locally advanced ER+ breast 
cancer. Upon closer inspection, it was found that 3 suppressed pre-treatment tumour levels 
of estrone sulphate (E1S), E1 and E2 by 90.1, 90.7, and 97.6 % respectively. For comparison, 
4 produced suppression levels of 72.9, 83.4, and 89.0 %, respectively.34 In 2008, Dixon et al.35 
confirmed that at clinical doses, 3 is more successful at reducing plasma estrogen levels, than 
4. In a randomised, double-blind study, 3 was the only AI that was shown to have significantly 
superior efficacy compared to a popular selective estrogen receptor modulator (SERM) – 1 – 
in the neoadjuvant setting with a better response rate (60 % versus 41 %). 3 was superior to 
1 in overall objective response rate (55 % versus 36 %) as well as breast-conserving surgery 
(48 % versus 36 %).36,37 In contrast to these findings, trials did not find any significant benefit 
in the tumour objective response of 3 when compared to 1. Objective response rate for 3 and 
1 was 39.5% and 35.4% respectively and breast-conserving surgery became feasible in 38.1% 
versus 29.9% of 3- and 1-treated patients, respectively.34 In a patient-preference study, those 
receiving 3 reported fewer adverse effects than those receiving 4 (43 % versus 65 % 
respectively), and more patients preferred 3 to 4 (68 % versus 32 % respectively).38 
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1.3 1H Nuclear Magnetic Resonance (NMR) Spectroscopy 
Nuclear Magnetic Resonance (NMR) is a physical event, where a given nucleus absorbs and 
re-emits electromagnetic radiation. Nuclear magnetic resonance was first measured and 
described in 1938 by Rabi et al.,39 who described how an oscillating magnetic field could  
induce a nucleus to flip their principal magnetic orientation. Yet, it was not until 1945 when 
NMR was successfully demonstrated. Independently, Felix Bloch and Edward Purcell detected 
the first significant observation of NMR in solids and paraffin, for which they were awarded 
the Nobel Prize in Physics in 1952, and thus begun the development of a new branch of 
science. 40 Today NMR is one of the most utilised analytical methods available, thanks to its 
versatility and ease of use, and it is most commonly used in structural determination and 
ascertaining the purity of a sample. NMR applies the quantum mechanics of subatomic 
particles (electrons, neutrons, and protons) due to their spin properties. In atoms such as 12C, 
16O and 32S where the spins are paired, the overall produced spin is zero as the pairs cancel 
each other out. Therefore, atoms which are used for routine NMR analysis are 1H, 13C, 15N, 
19F, 31P, etc. whose nuclei possess an overall spin of 1/2. The rule for determining the spin of 
a given nucleus, is if both the number of protons and neutrons are even, the nucleus will 
possess zero spin. If the number of protons and neutrons is odd after being added together, 
the nucleus will possess a half-integer spin (either 1/2, 3/2 or 5/2). If both the number of 




1.3.1 Magnetic Field Alignment  
During the NMR analysis, a magnetic field from a radiofrequency (RF) coil is applied to the 
system, promoting a transition of nuclei orientated with the magnetic field (parallel to the 
field, alpha = α) to those oriented against it (antiparallel to the field, beta = β) (Figure 2). The 
effect on their alignment is called the Zeeman Effect.42 When the RF is turned off, the 
relaxation of the nuclei begins, which means the transition of nuclei from β orientation back 
to α, until thermal equilibrium is reached. This process generates radiofrequencies, which are 
recorded by the NMR spectrometer and are displayed as a spectrum, following Fourier 
transformation.42 
Figure 2. A simplified diagram showing alignment of protons due to an external magnetic 




1.3.2 Chemical Shifts 
The radiofrequency which is detected in NMR spectroscopy is proportional to the magnetic 
field applied to the nucleus. Thus, it could be assumed that the resonance signal of a specific 
nucleus would have the same frequency value every time, feeding back to the user unhelpful 
information. However, due to chemical shift, multiplicity, the number of signals present and 
integral values, scientists can identify and characterise structures from their NMR signature. 
When applying an external magnetic field, the electrons respond in a way such that their 
motions produce a small magnetic field at the nucleus that usually acts in opposition to the 
externally applied field.40 Due to the change in the effective field on the nuclear spin, the 
signal frequency reported in the NMR spectrum shifts. The magnitude of the shift depends on 
the type of nucleus responding to the external magnetic field and the electron motion in the 
surrounding environment of atoms. The magnetic field produced by the electrons acts to 
either shield or deshield the nucleus. It is understood that with more shielding, a greater 
frequency is needed to bring the nuclei on resonance (i.e. lower chemical shift). Aliphatic 
nuclei, such as the methyl proton nuclei of an ethyl chain, are shielded in this way as the 
magnetic field produced by the electrons opposes that of the external magnetic field. 
Conversely, less shielded nuclei, such as aromatic nuclei, are deshielded (i.e. higher chemical 
shift) as the magnetic field produced by the electrons act to reinforce the external magnetic 





One of the limitations of NMR is its low sensitivity when compared to optical spectroscopic 
methods, which is caused by the very small population differences that exist between nuclear 
spin states. A way to improve the sensitivity of the NMR is through hyperpolarization. 
Hyperpolarization is the nuclear spin polarization of a material in a magnetic field, which 
exceeds the thermal equilibrium conditions determined by the Boltzmann distribution.45 
Hyperpolarization of solids, liquids, and gases can be achieved via a number of techniques: 
Dynamic Nuclear Polarization (DNP), Brute Force Polarization (BFP), Spin Exchange Optical 
Pumping (SEOP), Chemically Induced Dynamic Nuclear Polarization (CIDNP), Para-hydrogen 
Induced Polarization (PHIP) and Signal Amplification By Reversible Exchange (SABRE).45 
 
1.4.1 Dynamic Nuclear Polarization (DNP) 
In Dynamic Nuclear Polarization (DNP), polarization is transferred from a radical species to 
the substrate of interest via terahertz microwave irradiation near or at the Electron 
Paramagnetic Resonance (EPR) transition (more specifically a single quantum EPR transition 
which exists between a hyperfine coupled electron and nuclear spin). 46 This process can take 
upwards of hours to complete to a satisfactory polarization level. The sample of interest is 
polarized by dissolving or suspending it in glass-forming matrices doped with polarizing agents 
(typically a stabilised radical) at low temperature (100 K or less). 46 DNP was developed with 
a focus on frozen liquid samples and solid-state samples. DNP enhancements can reach 
several orders of magnitude under the right conditions (by up to 50,000-fold compared to 
thermal polarization)47, but there are some limiting factors which have to be overcome before 
it could be widely applied to drug discovery studies.46 Nuclei with short spin-lattice relaxation 
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time (T1) are difficult or near-impossible to detect, therefore identification of unknown 
compounds could prove to be challenging. The pre-condition of radical insertion to the 
sample is also an undesirable action after time-consuming purification of a product. This 
makes DNP an unfavourable method for NMR analysis, but is applicable to MRI, as it increases 
the sensitivity of 13C, which has a naturally low-background signal in the body.48 
 
1.4.2 Brute Force Polarization (BFP) 
Brute Force Polarization (BFP) is the simplest hyperpolarization method as it involves 
modification of magnetic field (B) and temperature (T) to generate hyperpolarization. With 
reference to Equation 1, B and T are the only terms that can be manipulated, as γ is the 
gyromagnetic ratio of the nucleus being examined, h is Planck’s constant and kB is the 
Boltzmann constant. 




BFP takes place in a high magnetic field (B > 14 Tesla (T)) and at a low temperature (T ≤ 4 K).49 
Lowering T prevents the population of higher energy level (linked to β-orientated spins) due 
to thermally linked effects, and increasing B helps with the promotion of α-orientated spins 
to β-orientated spins. Unlike DNP, no microwave excitation, free-radicals, or co-solvents are 
needed. This creates three obvious advantages. Firstly, there is no requirement to chemically 
alter the sample analyte. Secondly, due to BFP relying only on Boltzmann-law it is not limited 
to any specific types of samples. Thirdly, the absence of radicals avoids the need for 
downstream filtering and quality assurance.49 As Table 3 shows, BFP can deliver substantial 
gains in polarization. However, BFP does have limitations. Obtaining the required low 
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temperatures is challenging for hardware and requires cryogenic cooling. Some solvents are 
unsuitable e.g. dimethylsulfoxide due to incompatible freezing points. Furthermore, utilising 
strong magnetic fields for performing the NMR analysis requires substantial financial outlay.  
 Table 3. Polarization of 1H and 13C at different magnetic fields. 
 
1.4.3 Spin Exchange Optical Pumping (SEOP) 
Spin Exchange Optical Pumping (SEOP) is the most commonly used method for generating 
hyperpolarized noble gases. SEOP development begun when Kastler, who was awarded with 
the Nobel Prize for his work, demonstrated, that using circularly polarized laser light, an 
electronic spin order can be created in alkali metal vapours.50 Later discoveries showed, that 
adding 3He to the optically pumped alkali vapour atoms permitted polarization of 3He nuclear 
spins by spin-exchange collisions. This work has been extended to 129Xe, leading to the ability 
to produce large numbers of hyperpolarized noble gases with nuclear spin polarization levels. 
SEOP has advanced the resolution of MRI as noble gases, such as 3He and 129Xe, offer an 
improved method of determining the health and condition of lungs.51 This is important in a 
number of disease states, such as emphysema and cystic fibrosis. When compared to 
conventional MRI, which does not give any anatomical information of the inner lung space 
Nucleus Polarization at B0=1.5 T; T=310 K Polarization at B0=20 T; T=4 K 
1H 4.9 × 10−6 5.1 × 10−3 
13C 1.2 × 10−6 1.3 × 10−3 
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due to the low concentration of nuclei that can be interrogated (e.g. 1H) and computed 
tomography, which only images the first six branches of the lung, SEOP can image all 23 
branches of the lung using hyperpolarized noble gases. These gases, such as 3He and 129Xe, 
are used as imaging agents and offer clear and high-resolution images. Due to these gasses 
SEOP is a favoured method over DNP, when producing MRI agents.52 
 
 1.4.4 Chemically Induced Dynamic Nuclear Polarization (CIDNP) 
Chemically Induced Dynamic Nuclear Polarization (CIDNP) is defined as a non-Boltzmann 
nuclear spin state distribution produced under thermal conditions or through a 
photochemical reaction. Due to the highly nonperturbative nature, and short 
hyperpolarization time of ∼10–6 s, CIDNP has recently received considerable attention as a 
hyperpolarization tool for aromatic polypeptides, proteins, and amino acids in solution. It also 
provides a very useful tool for investigating radical pairs and elusive radicals.53 CIDNP works 
by forming a radical pair (RP) with a photoexcited photosensitizer.54 The nuclei experiencing 
notable hyperfine interactions with the unpaired electron will be the only one to experience 
the hyperpolarization, where the signal enhancements are usually proportional to the 
coupling constant. The photodegradation and the lack of uniform irradiation of the whole 
sample are the two main limitations of CIDNP. These limitations require alternative 






1.4.5 Para-hydrogen Induced Polarization (PHIP) 
Para-hydrogen Induced Polarization (PHIP) is a technique of hyperpolarization that depends 
on fast chemical reactions, that enables pairwise addition of para-hydrogen across 
unsaturated chemical bonds adjacent to 13C carboxyl or 15N nuclei (Figure 3). Para-hydrogen 
protons are paired in a singlet spin-state, which has no magnetic moment, which means they 
do not give rise to a signal when analysed via NMR.55 PHIP is more suited for chemical analysis 
and characterisation due to its speed, which is one of its main advantages, while the main 
disadvantage is the requirement for an unsaturated molecular PHIP precursor with 
appropriate asymmetry (for example 1,3-butadiene56).57 This proves to be a significant 
limitation for biological applications, although newly developed concepts using -OH 
protection in -C=C-O-R have significantly expanded the reach of molecular targets for PHIP. 58 
PHIP has three different approaches: Para-hydrogen And Synthesis Allow Dramatically 
Enhanced Nuclear Alignment (PASADENA), Adiabatic Longitudinal Transport After 
Dissociation Engenders Net Alignment (ALTADENA) and Signal Amplification By Reversible 
Exchange (SABRE).57 PASADENA and ALTADENA are hydrogenative forms of PHIP, whereas 
SABRE is non-hydrogenative. In PASADENA, polarization transfer occurs at high-magnetic field 
(i.e. in the magnet of the NMR spectrometer) alongside the detection of the polarized state. 
For ALTADENA and SABRE, polarization transfer occurs outside of the magnet (i.e. at low 
magnetic field) prior to rapidly transporting the sample to high-magnetic field for 







Figure 3. Schematic of the para-hydrogen-induced polarization (PHIP) process. Adapted from 
the publication by Kovtunov et. al. (2019)56 
 
1.4.5.1 Para-hydrogen And Synthesis Allow Dramatically Enhanced Nuclear 
Alignment (PASADENA) 
Para-hydrogen And Synthesis Allow Dramatically Enhanced Nuclear Alignment (PASADENA) 
is a unique method among other hyperpolarization methods due to its combination of 
effectiveness, speed, spectral quality, and the simplicity of the apparatus. PASADENA reaches 
high nuclear polarization within seconds in the liquid state by transforming the spin order of 
para-hydrogen to net polarization of a third nucleus like 13C by means of a spin-order-transfer 
(SOT) sequence.59 PASADENA is mostly used to study homogeneously catalysed hydrogen 
reactions and is characterised by the use of low-field and high-field magnets. This method is 
used for signal enhancement (up to a factor of 100,000-fold on currently utilized MRI 
scanners)59 but can also be used to evaluate reaction mechanisms and the kinetics involved 
in the reaction. The amplitude of the signal depends critically on the ratio of the J-coupling, 
which is an indirect interaction between two nuclear spins, that arises from interactions 
between the nuclei and bonding electrons.59 The limitation to this method is that it is 
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intrusive. The substrate is chemically changed after the addition of para-hydrogen, therefore 
reducing its effectiveness in certain areas of research.60 
 
1.4.5.2 Adiabatic Longitudinal Transport After Dissociation Engenders Net 
Alignment (ALTADENA) 
Adiabatic Longitudinal Transport After Dissociation Engenders Net Alignment (ALTADENA) is 
a method similar to PASADENA, which also requires an unsaturated substrate, as 
hydrogenation with para-hydrogen of an unsaturated bond is fundamental. The difference 
between them is the hyperpolarization method, seen in Figure 4. ALTADENA uses a non-
equilibrium population difference when hydrogenation at low magnetic field is followed by 
adiabatic transfer of the hydrogenated product to high magnetic field. This method adopts a 
concept known as ‘isotropic mixing’. In practice, samples can be polarized in the stray field of 
an NMR magnet, followed by the detection of the hyperpolarized state in a high-field magnet 
after the application of appropriate pulse sequences.61 Although ALTADENA is very similar to 
PASADENA regarding hyperpolarization, when comparing spectra obtained through the two 
methods, it is clear that ALTADENA is more efficient. This is due to the sample being slowly 
transferred towards the NMR magnet, where polarization differences are created, and their 
amplitude can be larger. It is stated that high para-hydrogenation rates for both PASADENA 




Figure 4. Schematic representation of the NMR characteristics and spin configurations. In 
ALTADENA only the lower energy βα spin state is populated. Under ALTADENA conditions, 
only two components are observed for each resonance, each with a different phase. The 
conditions corresponding to PASADENA result in the obtained 1H NMR signals possessing 
characteristic out of phase signals, appearing as two equally intense pairs; one line pointing 
upwards for absorption, and a second pointing downwards, for emission. Adapted from the 
publication by Fekete et. al. (2015)63 
 
1.4.5.3 Signal Amplification By Reversible Exchange (SABRE) 
Signal Amplification By Reversible Exchange (SABRE) is another para-hydrogen based 
hyperpolarization technique, which enhances sample detectability. SABRE differs from 
PASADENA and ALTADENA as it is non-hydrogenative. SABRE predominantly uses iridium-
centred catalysts to propagate polarization transfer.55 These catalysts enable exchange of 
substrate and para-hydrogen-derived hydrides at the metal centre. Polarization is transferred 
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from the para-hydrogen-derived hydrides to substrate spin 1/2 nuclei through the J-coupling 
network that is established. A weak polarization transfer field (typically 65 × 10−4 T for 1H) is 
used to facilitate polarization transfer. Substrate molecules trans to para-hydrogen-derived 
hydrides are optimally polarized whereas those that are cis receive no polarization (as the J-
coupling is effectively zero). The polarization is transferred from para-hydrogen derived 
hydride ligands to the protons of an analyte trans to it via the establishment of J-coupling 
(scalar) network (Figure 5).64 Hyperpolarization is acquired by dissolving para-hydrogen in a 
solution containing the target analyte within a weak polarization transfer field (typically 65 x 
10-4 T for 1H) and the active SABRE catalyst.64 
The iridium catalyst (Figure 5) has undergone extensive development to tune ligand and 
hydride exchange rates to maximise polarization transfer. The catalyst enables biocompatible 
SABRE hyperpolarization with heterogeneous catalyst in aqueous media with the ability to 
recycle the catalyst.65 This method provides renewable hyperpolarization provided the para-
hydrogen atmosphere is refreshed routinely. Notably, unlike PHIP, SABRE does not lead to 
the chemical composition of the analyte becoming changed. This entails a much larger scope 
of molecules that can be investigated as it does not need an unsaturated bond to be present.66 
The use of a catalyst does not increase the experimental time greatly, as the activation can 
occur at ambient temperatures (catalyst decomposes upon heating)67 and without the need 










Figure 5. Simplified diagram of SABRE hyperpolarization with iridium catalyst (centre). 
Adapted from the publication by Semenova et. al. (2018)66 
 
1.5 Hyperpolarization of Letrozole 
One of the major challenges in cancer biology is monitoring and understanding cancer 
metabolism in vivo with the sole goal of improved diagnosis and therapy. Tracer methods are 
required to detect specific enzyme-catalysed reactions, as the crucial metabolites (L-
octanoylcarnitine, 5-oxoproline, hypoxanthine, and DHA)68 are low in concentration and, 
therefore, beyond the detection range of traditional magnetic resonance methods. A solution 
to this is hyperpolarization, which can improve sensitivity by a factor of 10,000 or more.69 All 
the methods mentioned in sections 1.4.1-1.4.5.3 can induce hyperpolarization. However, the 
hyperpolarized state value decreases with a time constant according to the spin-lattice 
relaxation time (T1) once the hyperpolarized compound is delivered in vivo. Because of this, 
the signal may be significantly reduced during in vivo detection to unmeasurable levels. This 
gives rise to challenges in that T1 has to be long enough so that a large enough number of 
hyperpolarized states is preserved in vivo, or that the relevant pathways or processes being 
studied must occur sufficiently quickly so that useful information can be obtained. Although 
T1 is a big imaging limitation for in vivo studies, unlike nuclear medicine probes, the images 
29 
 
can be taken without waiting for the for clearance of hyperpolarized probes. The 
hyperpolarized probes are produced ex situ and introduced into biological systems, allowing 
images to be taken immediately after the administration of the probe. The probes are 
detected with high sensitivity and contrast against background signals providing information 
on biodistribution, uptake and metabolism of the probe in a scan time of a minute or less.70 
This approach provides clear advantages, such as the ability to image metabolic activity of 
cells immediately after the administration of the probe or the observation of a fast-metabolic 
flux. In many cases, it was found that the polarization of 13C and 15N molecular sites would 
persist for much longer compared to other nuclei, such as protons, with a hyperpolarization 
relaxation time of a few seconds or less. This is due to 13C and 15N possessing a low gamma 
(γ) compared with that of 1H. As polarization is a product of low-γ of the nucleus being studied 
and the applied magnetic field strength in which the nuclei are situated, weak signals can be 
enhanced by transfer of polarization from spins with high magnetic moments (1H) to nuclear 
spins with lower magnetic moments (13C and 15N).69,70 In previous reports, it was found that 
15N sites interact directly with the iridium catalytic centre of the polarization transfer catalyst 
[Ir(IMes)(COD)Cl] (COD = cis,cis-1,5-cyclooctadiene, IMes = 1,3-bis(2,4,6-trimethyl-
phenyl)imidazole-2-ylidene), which is used in SABRE experiments.69 This catalyst facilitates 
the polarization transfer from para-hydrogen derived hydrides to 15N sites. Pyridine was one 
of the first compounds to be polarized by SABRE, followed by other studies using numerous 
pyridine derivatives.71 These experiments have shown that pyridyl-analogues antibiotics e.g. 
metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol 9), has been polarized to a level of 
15%, compared to non-hyperpolarised thermal spectra, which persists for tens of minutes at 
1.4 T when applied SABRE hyperpolarization when compared to its non-hyperpolarised 
thermal spectra.71 It important to note the concentration of 15N nuclei is consistent. These 
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results give strong foundations for letrozole to successfully hyperpolarize due to its triazole 
ring, which can be mapped onto pyridine or molecule 9 seen in Figure 6, which is an excellent 
delivery vehicle because its three 15N sites carry thrice the hyperpolarization payload of 





Figure 6. Structures of pyridine (a), 9 (b) and 3 (c). The 15N sites on (a) and (b) can be 
hyperpolarized with relaxation time constants ranging from 1 min to 10 min. Due to the 
similarities in the nitrogen rings, it was reasonable to assume that 3 will hyperpolarize. 
Another factor which could help predict how well a molecule could be hyperpolarised is the 
pKa values. The pKa values of pyridine, imidazoles and triazoles are 5.2, 6.9 and 9.3 
respectively.73 Pyridine’s low pKa value, means it is the strongest Lewis acid out of the three 
rings and it will accept the electrons the best. This positively affects the hyperpolarisation 
strength, making pyridine one of the best compounds in terms of hyperpolarisation 
strength.74 Imidazole has a higher pKa than that of pyridine hence it doesn’t accept electrons 
as strongly as pyridine, making the hyperpolarisation strength lesser than pyridine’s. 
Triazole's pKa of 10.3 is the highest. When following the trend, triazole will hyperpolarize to 






1.6 Gas chromatography mass spectroscopy (GC-MS)  
 Gas chromatography mass spectroscopy (GC-MS) was one of the methods utilised to 
characterise compounds used in this thesis. GC-MS is a technique that is used when analysing 
several similar compounds, due to chromatogram’s high precision and accuracy for GC active 
compounds. This analytical method was used to analyse the synthesized products in order to 
confirm the successful synthesis as well as the purchased compounds to ensure they could be 
used without the need for purification. All the compounds analysed in this report have a 
similar structure, making the use of GS-MS, a valid characterisation method. GC-MS is split 
into two components: The Gas Chromatograph (GC) and the Mass Spectrometer (MS) (Figure 
7). 
 
Figure 7. A simplified diagram of GC-MS with the key components labelled. Figure adapted 
from a diagram by Emwas et al.75 
The Gas Chromatograph is responsible for separating a mixture of analytes based on their 
relative volatilities. The sample is injected into the GC using the syringe and is then mixed with 
the mobile phase (carrier gas) inside the inlet, which then carries the sample into the column. 
The analytical column has a stationary phase coated on the inside walls. The analytical column 
is held in the GC oven that is heated during the analysis to elute the less volatile components. 
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The details of the method can be seen in Section 3.2. The outlet of the column is inserted into 
the detector located at the transfer line that responds to the chemical components eluting 
from the column to produce a chromatogram. As the compounds elute and pass through the 
detector (in this case the MS) the concentration of molecules which are detected is directly 
proportional to the peak area. The result is a chromatograph, which is a plot of relative 
response over the retention time (Rt). 
The Mass Spectrometer component of the GC-MS system is a specialised detection method 
used to identify the structure of analytes as they elute from the GC-column. The molecules 
that elute from the GC column are first ionised within the ion source (a beam of electrons) to 
produce positively charged molecular ions which rapidly degrade into fragment ions – this is 
known as electron impact ionisation. The fragment and molecular ions are then separated in 




2. Aims and Objectives  
The aim of this thesis was to demonstrate that the clinically approved drug 3 could be 
hyperpolarized via SABRE, to obtain a hyperpolarized 1H NMR spectra, as well as to investigate 
if the size of molecules affect the amount of hyperpolarization when using the same 
hyperpolarization method. 
The objectives were to hyperpolarize molecule 3 and determine the amount of 
hyperpolarization by measuring the peak enhancement (ε) and to collect data for the 
compounds 1,2,4-triazole 10a, 1-methyl-1H-1,2,4-triazole 10b, 1-benzyl-1,2,4-triazole 10c,    
4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile 10d, 1-[di(phenyl)methyl]-1H-1,2,4-triazole 10e 
using the same method, and using the acquired data to devise a pattern in between the 




3. Experimental  
3.1. Instrumentation 
All NMR spectra for characterisation of synthesised compounds were collected on a JEOL ECS-
400 FT NMR in the solvent described with chemical shifts (δ) quoted in ppm and coupling 
constants (J) quoted in hertz (Hz). Spectra were collected at a frequency of 400.14 MHz for 1H 
spectra and 101 MHz for 13C spectra.  
SABRE NMR spectra were collected on an Oxford Instruments Pulsar benchtop at a frequency 
of 59.8 MHz for 1H spectra. NMR analysis was carried out making use of MestReNova version 
11.0.4 and ACD/Labs version 2020.1.2. SABRE measurements above earth’s magnetic field 
were accomplished using a custom electromagnet produced by Siga Transformers 
(sigatransformers.co.uk) within which a vertical magnetic field of up to 150 G could be 
generated. A Hirst Magnetic Instruments Ltd GM07 gaussmeter serial #10620 with transverse 
(Hirst magnetic instruments Ltd, Cornwall, UK) and axial stock number 212-736 (RS 
components Ltd, Northants, UK) hall probes were used to determine the exact magnetic field 
for measurements which involved polarization transfer occurring under SABRE conditions.  
Purification was carried out using flash chromatography performed on a Biotage Isolera One 
System equipped with Isolera Assist (Biotage GB Limited, Hengoed, CF82 7TS) using Biotage 
Sfär columns and a mobile phase consisting of EtOAc:hexane (1:3). 
Hydrogen was generated using a Peak scientific PH200 hydrogen generator (Peak Scientific 
Instruments Ltd, Inchinnan, UK) set to 3.5 bar. Where para-hydrogen was required this was 
generated through the immersion of a charcoal packed coil into liquid nitrogen to generate 
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~50% enriched para-hydrogen. SABRE measurements were made utilising GPE scientific, 
5mm, 7’’ long, 400 MHz, Norell select series Young’s tubes. 
Gas Chromatography – Mass Spectrometry (GC-MS) analysis was performed on an Agilent 
7890B GC coupled to an Agilent 5977B Mass Spectrometer (Agilent Technologies, Cheadle, 
UK). The GC-MS method was carried out using 0.5 μL injection split 50:1 with an inlet 
temperature of 265 °C. A hold time of 3 minutes at 50 °C was utilised, with ramps of 30 °C/min 
for 8 minutes, then a further hold time of 6 minutes at 290 °C. Helium was used as a carrier 
gas at a rate of 1.2 mL/min through a HP5-MS column (30 m x 0.25 mm x 0.25 μm).  
Infrared analysis was performed on a PerkinElmer FTIR (PerkinElmer, Llantrisant, UK) with 4 
scans acquired across the range 4000 – 400 cm-1. 
 
3.2 Chemicals 
All materials were sourced from Acros Organics (Loughborough, UK), Sigma-Aldrich 
(Gillingham, UK), Fisher Scientific (Loughborough, UK) or Apollo chemicals (Tamworth, UK). 
All materials were used as received unless stated within the experimental procedure. The 
SABRE pre-catalyst, [Ir(IMes)(COD)Cl], was prepared by Dr. Thomas Robertson76 and used as 
received. Solvents were purchased from Fisher Scientific and were of general use or HPLC 
grade unless specifically stated. Where the use of dry ethyl acetate is stated, it was dried over 
anhydrous potassium carbonate and then distilled prior to use. TLC analysis made use of 
aluminium backed silica gel 60 F254 plates (Merck Millipore). Deuterated solvents were 









4-[(4-Cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile (Letrozole) was obtained from 
Fluorochem (Glossop, UK) [Batch No. H1377] and used without further purification. 1H NMR 
(400 MHz, CD3OD) δ (ppm): 8.50 (1H, s, NCHN), 7.99 (1H, s, NCHN), 7.67 (4H, d, CH), 7.34 (4H, 
d, CH), 7.12 (1H, s, CH); 13C{1H} NMR (100.5 MHz, CD3OD) δ (ppm): 153.1, 145.9, 144.2, 133.8, 
130.4, 119.1, 113.7, 66.8; ; ATR-FTIR ν (cm-1): 3120 (CH, m), 2231 (CN, s), 1743-1607 (CH, w, 
aromatic overtones), 1275 (C=N, s); MS (m/z - ESI): 217 (BS), 284 (M+), 285 ([M+H]+); RRT: 
1.41; mp 187 – 191 °C [183 – 185 °C (lit.77)]. 
 
1,2,4-Triazole (10a)  
 
1,2,4-Triazole was obtained from Fluorochem (Glossop, UK) [Batch No. FCB033416] and used 
without further purification. 1H NMR (400 MHz, CD3OD) δ (ppm): 8.10 (2H, s, NCHN); 13C{1H} 
NMR (100.5 MHz, CD3OD) δ (ppm): 147.6; ATR-FTIR ν (cm-1): 3128 (CH, m), 3119-3032 (CH, 







1-Methyl-1H-1,2,4-triazole was obtained from Fluorochem (Glossop, UK) [Batch No. 
FCB044065] and used without further purification. 1H NMR (400 MHz, CD3OD) δ (ppm): 8.27 
(1H, s, NCHN), 7.86 (1H, s, NCHN), 3.79 (3H, s, CH3); 13C{1H} NMR (100.5 MHz, CD3OD) δ (ppm): 
152.0, 145.4, 36.4; ATR-FTIR ν (cm-1): 3114 (CH, w), 2949 (CH, w), 1511 (CH, s), 1272 (C=N, s); 
mp 21-22 °C [20 °C (lit79.)]. 
 




The target compound was prepared using the method reported by Wood et al.80 Sodium-
1,2,4-triazole (1.06 g, 15.3 mmol), potassium carbonate (1.41 g, 10.2 mmol) and potassium 
iodide (0.10 g, 0.60 mmol) were sequentially added to benzyl bromide (1.74 g, 10.20 mmol) 
in acetone (50 mL). The reaction mixture was heated at 55 °C and left to stir for 24 h. The 
solution was left to cool, followed by addition of water (100 mL). The product was extracted 
using ethyl acetate (EtOAc, 2 × 50 mL). The organic layer was washed twice with aqueous 
NaOH (1 M, 50 mL) and brine (3 × 50 mL) before being dried (MgSO4). The solvent was 
removed under vacuum. The crude product was purified by flash chromatography 
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(EtOAc:hexane [1:2]) to give the title compound as an off white solid (0.77 g, 28%); 1H NMR 
(400 MHz, CD3OD) δ (ppm): 8.42 (1H, s, NCHN), 7.87 (1H, s, NCHN), 7.24-7.19 (5H, m, C(Ar)-
H), 5.30 (2H, s, CH2); 13C{1H} NMR (100.5 MHz, CD3OD) δ (ppm): 152.3, 145.1, 136.8, 129.9, 
129.4, 129.1, 54.2; ATR-FTIR ν (cm-1): 3126 (CH, m), 3103 (CH, m), 1958-1714 (CH, w, aromatic 
overtones), 1275 (C=N, s); MS (m/z - ESI): 91 (BS), 158 (M+), 159 ([M+H]+); RRT: 0.73; mp 60-







4-(1H-1,2,4-Triazol-1-ylmethyl)benzonitrile was obtained from Fluorochem (Glossop, UK) 
[Batch No. FCB090713] and used without further purification. 1H NMR (400 MHz, CD3OD) δ 
(ppm): 8.50 (1H, s, NCHN), 7.90 (1H, s, NCHN), 7.62 (2H, d, CH), 7.34 (2H, d, CH), 5.42 (2H, s, 
CH2); 13C{1H} NMR (100.5 MHz, CD3OD) δ (ppm): 152.7, 145.5, 142.4, 133.7, 129.8, 119.3, 
113.2, 53.4; ATR-FTIR ν (cm-1): 3103 (CH, m), 2226 (CN, s), 1750 (CH, w, aromatic overtones), 










The target compound was prepared using the method reported by Wood et al.80 
Diphenylmethanol (1.5 g, 8.22 mmol), 1,2,4-triazole (0.68 g, 9.87 mmol) and para-
toluenesulphonic acid (0.65 g) were dissolved in dry toluene (100 mL) and heated at reflux 
equipped with a Dean-Stark trap for 36 h. The reaction mixture was allowed to cool, and the 
solvent was removed under vacuum. The resulting residue was dissolved in EtOAc (300 mL), 
washed with 1 M NaOH (2 × 100 mL) and brine (3 × 50 mL), dried (MgSO4) and the solvent 
was removed in vacuo. The crude product was dissolved in hot dry EtOAc (30 mL) and hexane 
(15 mL) was added dropwise. Upon cooling to room temperature orange crystals were 
obtained. The crystals were dissolved in minimum amount of EtOAc and purified using Biotage 
flash chromatography (EtOAc:hexane [1:2]) to give the target compound as orange crystals 
(1.35 g, 62%); 1H NMR (400 MHz, CD3OD) δ (ppm): 8.02 (1H, s, NCHN), 7.90 (1H, s, NCHN), 
7.36 (6H, m, CH), 7.13 (4H, m, CH), 6.76 (1H, s, CH); 13C{1H} NMR (100.5 MHz, CD3OD) δ (ppm): 
152.0, 144.8, 139.3, 129.4, 129.0, 128.8, 68.1; ATR-FTIR  ν (cm-1): 3387 (CH, m), 3103 (CH, m), 
1963-1769 (CH, w, aromatic overtones), 1445 (CH, m), 1271 (C=N, m); MS (m/z - ESI):  167 






3.3 SABRE hyperpolarization - Enhancement calculations 
Enhancement factors were calculated using Equation 2, where |Shyp| is the integral of a set 
region following hyperpolarization and |Sthermal| is the integral of the same set region without 
hyperpolarization. 
Equation 2.  𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 (𝜀)= |𝑆ℎ𝑦𝑝| / |𝑆𝑡ℎ𝑒𝑟𝑚𝑎𝑙| 
The same experimental sample was used for the collection of |Shyp|  and |Sthermal|, however, 
|Sthermal| was allowed to fully relax in the measurement field of 1.4 T, see Section 3.2) before 
data collection. The polarized and reference spectra were collected using identical 
parameters for comparison reasons. To determine the enhancement level, the raw integrals 
of the relevant resonances in the polarized and unpolarized spectra were used. To ensure a 
fair comparison for all samples, each spectrum was properly referenced to the solvent peak 
and the same chemical shift region was selected for integrals. 
 
3.3.1 SABRE sample preparation  
Unless otherwise specified, a sample of ligand (L) was solvated in 600 μL of deuterated 
methanol with 1.92 mg of the SABRE pre-catalyst, [Ir(IMes)(COD)Cl]. The details of the 
amounts that were used for this experiment can be seen in Table 4. For continuity reasons, 
the desired concentration for each compound was 0.02 M. The ratio of ligand to pre-catalyst 
was, the same throughout, with four equivalents ligand:pre-catalyst. The sample transfered 
into a Young’s capped NMR tube, followed by vigorous shaking to ensure full ligand and pre-
catalyst solvation. The sample was then freeze-thaw degassed, using the procedure that 
involved submerging the tube in a dry ice and acetone bath, followed by creating a vacuum 
using a Schlenk line. Para-hydrogen was pumped to the capped tube at a pressure of 2.5 bar, 
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followed by the acquisition of the thermal (Boltzmann) one scan-spectrum using a low-field 
60 MHz Oxford Pulsar benchtop NMR instrument. The tube was then shaken for 2 minutes in 
order to activate the catalyst inside and refilled with para-hydrogen, this time increasing the 
pressure to 3.0 bar. The NMR tube was shaken vigorously for 10 seconds in earth’s magnetic 
field in the vertical plane. After 10 seconds the tube was immediately transferred to the 
spectrometer to collect the 1H NMR spectrum. This method has been repeated three times to 
produce a set of triplicate data. It is important to shake the tube vertically, as the magnetic 
field reading in vertical direction is around 0.5 G whereas horizontally it is around 0 G. Due to 
the composition of the tube (liquid at the bottom, gas at the top), this method gives much 
better mixing of the biphasic components to ensure maximal polarisation transfer. The whole 
process was repeated, but this time the tubes were shaken inside a coil, which created a 
magnetic field of 65 G. After shaking for 10 seconds, the tube was immediately transferred to 
the spectrometer to collect the 1H NMR spectrum. This method was again repeated three 
times to produce a set of triplicate data. 








1 10a 0.83 1.92 0.6 
2 10b 0.99 1.92 0.6 
3 10c 1.91 1.92 0.6 
4 10d 2.21 1.92 0.6 
5 10e 2.82 1.92 0.6 




4. Results and Discussion 
Six compounds, 10a - e and 3, were analysed herein. Four compounds were purchased from 
commercial sources, whereas the remaining two compounds, 10c and 10e, were synthesised. 
The synthetic method for the preparation of 10c and 10e is outlined in Scheme 1 and Scheme 
2 respectively.  
 
Scheme 1. The proposed mechanism for the formation of N-benzyltriazole (10c).  
As seen in Scheme 1, 10c is formed by a SN2 reaction between sodium triazole and benzyl 
bromide. A yield of 28% was obtained which is lower than that reported by Schwärzer et al. 
(50%).84 The starting materials were dissolved in acetone to ensure all the reactive species 
are able to interact, allowing the triazole to undergo nucleophilic attack of benzyl bromide. 
The solvent played a significant role in the reaction. Using acetone as the solvent raises the 
reactivity of the nucleophile, due to its lack of hydrogen-bond donating capability. Acetone 
does not form hydrogen bonds with the anionic nucleophile, which means there is a relatively 
weak interaction between the aprotic solvent and the nucleophile. The treatment of benzyl 
bromide with an alkali metal halide (in this case potassium iodide, KI) leads to replacement of 
the halogen via a SN2 reaction, as explained by the Finkelstein Reaction.85 This is achieved by 
an equilibrium process, where the driving force for the reaction is the solubility of salts (KI) 
and the presence of acetone which shifts the equilibrium of the reaction. The substitution of 
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bromide in benzyl bromide with iodide in acetone leads to the desired iodide product, since 
potassium bromide is insoluble in acetone and, therefore, is consequently removed from the 
equilibrium equation, causing the reaction to shift towards the products. Iodine is a much 
better leaving group than bromine, because iodine is bigger, therefore C-I is longer and that 
makes it weaker.86 Therefore, in the second step of the reaction the newly formed C–I bond 
can be easily broken, and the iodide will be replaced by a far weaker nucleophile, triazole. 
During this step, iodide is regenerated, and the cycle starts again. 
Scheme 2 shows the reaction mechanism for the formation of 10e. The yield, as reported by 
Doiron et al. is 51%.83 This compares well to the 62% yield obtained herein. The starting 
materials were dissolved in acetone to ensure all the reactive species were able to interact, 
allowing the triazole for nucleophilic attack. This involves the protonation of the -OH group 
by the para-toluenesulphonic acid, which results in the creation of an R-OH2+ moiety. The 
triazole nucleophile then attacks the diphenylmethanol ion and the moiety is activated, and 
thus bond-forming and bond-breaking occur simultaneously, releasing water, a weak base, as 
a leaving group, forming 10e.87 






4.1 Retention times (Rt) 
Retention time (Rt) is a measure of the time taken for a solute to pass through a 
chromatography column. The longer retention time depends on the interaction of the analyte 
with the stationary phase. Table 5 shows the retention times and the relative retention time 
of molecules 10c - e and 3 (entries 1, 2, 4 and 5). The reference for the relative retention time 
was the internal standard, eicosane, which eluted at 7.220 min. Compounds 10a and 10b 
were not detected by this methodology; a likely reason for this observation is that the 
molecules have broken down in the oven due to the heat, and never reached the detector. 
As seen in the Table 5, the retention time increases every time the molecule gets more polar. 
Retention time is affected by many factors, including the carrier gas flow rate, column length, 
column temperature and the amount of material injected. All these factors remained the 
same, in order to make the results comparable. The changing factors were the vapour 
pressure, which varies depending on the boiling point of the molecule and the polarity of the 
samples. The lower the boiling point is, the higher the vapour pressure of the compound, 
meaning the compound will spend more time in the gas phase with very few interactions with 
the stationary phase, shortening the retention time. The retention time increases if the 
polarity of the compound and the stationary phase are similar because the interactions 
between the two are stronger. The stronger the interaction is, the more time it takes to 
migrate through the column, due to longer interactions of the compound with the stationary 
phase. The size is also known to affect the retention time because generally, the greater the 
molecular weight of a compound, the lower its volatility. As expected, the retention time, as 
well as the relative retention time increases as molecules become bigger, due to the increase 
of their boiling point and column interactions causing the molecule to stay inside the column 
for a longer period of time before reaching the GC-MS detector. 
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Table 5. GC-MS retention times of molecules 10c - e and 3 
Entry Molecule Retention Time (min) 
Relative retention 
time (RRT) 
1 10c 5.27 0.73 





4 10e 7.40 1.02 
5 3 10.18 1.41 
 
4.2. Mass spectra 
On top of the retention times, GC-MS allowed for characterisation of the four compounds  
10c - e and 3 by analysing their mass spectra. The mass spectrum provides two key concepts 
for each molecule: base peak and parent ion peak. The parent ion peak, which is also called 
the molecular ion peak, represents the mass of the original molecule. The base peak 
represents the most abundant component and is the largest peak in the spectrum. The base 
peak is almost always the most stable ion in the mixture. The mass spectrum of 10c (Figure 
A6 in the appendix) shows a peak at m/z 159, which is the molecular ion peak and a base beak 
at m/z 91, which is likely to be a benzyl carbocation (tropylium ion). The mass spectrum of 
10d (Figure A9 in the appendix) has a visible peak at m/z 184, which is responsible for the 10d 
molecular ion, and a base peak visible at m/z 116 that is the 4-cyanobenzyl carbocation. The 
mass spectrum of 10e (Figure A12 in the appendix) has a visible molecular ion peak at m/z 
235, and a base peak at m/z 167, which would represent the diphenylmethyl ion. The 
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spectrum on 3 (Figure 8) has a molecular ion at m/z 258 and a base peak visible at m/z which 
represents the 4,4’-dicyanodiphenylmethane (Table 6). 
Figure 8. GC-MS spectrum of 3 with visible molecular ion and base peaks as well as the 
corresponding structures of fragments 
Table 6. Table showing mass/charge values and the structures responsible for the peaks 
 
4.3 Infrared Spectroscopy (IR) 
Infrared Spectroscopy (IR) was the second analytical method which was used for 
characterisation of synthesised and purchased compounds. IR is the analysis of infrared light 
interacting with a molecule. Infrared light is part of the electromagnetic radiation span. The 








of 750 nm–100 μm. This range of wavelengths corresponds to a frequency range of 430 
terahertz (THz) to 300 gigahertz (GHz).88 In this report, IR was used to determine the 
functional groups in molecules based on their frequency (wavenumber). IR spectroscopy 
measures the vibrations of atoms allowing to determine the functional groups present in a 
sample. After passing infrared light through a sample, an infrared spectrum is obtained with 
peaks corresponding to the frequency of absorbed radiation. Each group of bonds have their 
characteristic vibrational frequencies, allowing the characterisation of a molecule. The 
measurement obtained is an infrared spectrum, which is a plot of measured infrared intensity 
versus wavenumber. Figure 9 and Figure 10 show IR spectra of molecules 10c and 3 
respectively. 
Figure 9. IR spectrum of 10c 
 





































































At first glance, the two figures are similar. Both Figure 9 and Figure 10 contain medium C-H 
stretching peaks at 3126 and 3120 cm-1 respectively, as well as 690–900 cm−1 for out-of-plane 
C-H bending. Weak aromatic overtones are visible on both spectra in the 1958-1714 cm-1 
regions, which indicate the presence of the benzene rings on both molecules. Both figures 
also contain a carbon-nitrogen double bond peak, at 1275 cm-1 in both cases, which is a part 
of the triazole ring. The only difference between the two figures, is the strong nitrile 
functional group peak, which can be seen in Figure 10 at 2231 cm-1 for C ≡ N stretching. This 
peak is absent from Figure 9. The same nitrile functional group peak is present when the 
spectrum of 10d is interrogated (Figure A8 in the appendix), which is absent from all the other 
collected spectra (Figure A1, A3, A11 in the appendix). Spectra collected by Hayat et al.74 for 
sample 10c gives near identical wavenumber values to the ones acquired in this report. The 
same can be said about the collected results for 3, which were compared to the reported 
values by Elzoghby et al.89 that proved to be highly similar. These findings further validate the 
successful characterisation of both compounds. 
 
4.4 High Field 1H NMR  
High-field 1H NMR spectra were collected for all the compounds analysed. When comparing 
the collected data to literature, there are near negligible differences in peak values. According 
to a report by Kumar et al.90 the chemical shift for NCHN peak of synthesized 10a appeared 
at 8.32 ppm in the 1H NMR spectrum, which compares well to the commercially purchased 
sample, in which the peak appeared at a chemical shift of 8.10 ppm (Figure 11). The same 
minor differences in chemical shifts can be seen throughout most of the spectra. Suman et 
al.91 has reported the chemical shifts of the two NCHN peaks on synthesized 3 to be δ8.09 and 
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δ7.71. These chemical shifts are the only ones which appear to be significantly lower when 
compared to the chemical shifts of the same peaks from a commercially acquired 3. As seen 
in Table 7, the chemical shift of 1H, s, NCHN and 1H, s, NCHN were 8.50 and 7.99 ppm 
respectively (Figure 12). It is likely, that the change in chemical shifts was an effect of the use 
of different solvents as well as different NMR machines. As reported by Dracinsky92, different 
solvents have an effect on the chemical environments such as magnetic shielding and indirect 
spin−spin coupling constants, therefore changing the chemical shifts. 
The reason for focusing primarily on the NCHN peaks is because these peaks are the focus 









Figure 11. 1H NMR spectrum 10a collected in methanol-d4 (solvent peaks present at the 













Figure 12. 1H NMR spectrum of 3 collected in methanol-d4 (solvent peaks present at the 
chemical shifts δ 4.78ppm and 3.31ppm)  
 
It is widely known that structural changes and almost any genuine binding interaction will 
affect the very sensitive chemical shift. Table 7 shows the change in chemical shift as the size 
of the molecule increases. Only the peaks on the 1,2,4-triazole group were focused on due to 
these peaks being the focus of the SABRE study (Section 4.7). The two hydrogens responsible 










Figure 13. Drawing of the 1,2,4-triazole functional group with highlighted HA and HB atoms for 
easier distinction between the two protons. 
Table 7. Table of selected chemical shift values for molecules of interest. 
 
Table 7 shows small, regular chemical shift changes throughout the table, with values 
increasing steadily more downfield from 10a to 10d. The distinctive pattern for a substituted 
10a is the pair of singlets, visible in molecules 10b - e and 3. The is a clear difference in 
chemical shift between peaks in each molecule. As the molecules get more complex, the 
difference in chemical shift between the molecules get smaller. HA on carbon 5 and HB on 
carbon 3 on the 1,2,4-triazole ring are split into two peaks for molecule 10b, and onwards, 
due to the symmetry being broken by the addition of functional groups. The protons are no 
longer magnetically equivalent, hence two peaks can be seen. The chemical shift values for 
10c have increased when compared to 10b due to the addition of the aromatic ring. The 
protons on the aromatic ring are shifted downfield. This is due to the electrons on the 
aromatic ring being free to circulate, rather than being fixed in place in bonds which causes 
Molecule: Chemical shift δ (ppm): 
10a 8.10 (2H, s, NCHN ) 
10b 8.27 (1H, s, HA) 7.10 (1H, s, HB) 
10c 8.42 (1H, s, HA)  7.87 (1H, s, HB) 
10d 8.50 (1H, s, HA) 7.90 (1H, s, HB) 
10e 8.25 (1H, s, HA)  7.95 (1H, s, HB) 
3 8.50 (1H, s, HA) 7.99 (1H, s, HB) 
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aromatic ring current, that dramatically influences the chemical shifts. The free-flowing 
electrons in aromatic rings are part of the π electron system, which interact more strongly to 
the magnetic field with the applied magnetic field and begin to circulate. As a result of this, 
the nearby protons will experience 3 fields: the shielding field, the applied field, and the field 
due to the π system. This causes a notable chemical shift change between molecules 10d and 
10e.  
Molecule 10d has the chemical shift value of 8.50 ppm for HA, but molecule 10e has the 
chemical shift value of 8.25 ppm. The key difference between these molecules is the addition 
of a second aromatic group and the absence of the nitrile group on molecule 10e, as election 
density around the proton heavily influences the chemical shift. 10d has an electronegative 
nitrile group, which decreases the electron density, causing the proton to be less shielded, 
which in turn increases the chemical shift.  
Molecule 10e undergoes a non-uniform magnetic field, or anisotropy, which causes the 
frequency of the absorption to change, causing electrons in 10e to become shielded, 
decreasing the chemical shift. Another example of the effect of the electromagnetic nitrile 
group can be seen in molecules 10c and 10d. The only difference between these molecules is 
the nitrile group, which is absent from 10c. The electron density is deshielding the protons on 
10d, which causes the small difference in chemical shift; 8.42 and 7.87 ppm compared to 8.50 
and 7.90 ppm for 10c and 10d respectively. These minor changes help with understanding 
how the hyperpolarized peaks will form, and where on the spectrum they will appear, based 





4.5 Low-field 1H NMR  
All molecules 10a - e and 3 have been characterised using 1H bench-top NMR (Figure 14). Each 
signal can be assigned to its corresponding hydrogen environment. When comparing the 
bench-top spectra to the high field 1H NMR (Figure 15A and 15B), the resolution suffers 
greatly with signals in Figure 15B appearing broader and less sharp. On the contrary, bench-
top NMR’s time efficient procedures, the ease of use and portability outweigh the small 
setbacks. Signals are present in the aromatic region for 10a - e and 3, due to phenyl groups 
being present. The peaks of interest are located at δ ~8.6 for proton HA and ~8.0 for proton 
HB (marked with ◆ for HA and◆ for HB, seen Figure 14). These represent the hydrogens 
present on the triazole ring, which will undergo hyperpolarization, as these are closest to the 
nitrogen donor atoms. The position of nitrogen on the triazole, as well as the functional group 
attached to N1, breaks the symmetry, causing two environments to appear. These 
environments are not visible for 10a due to the molecule being symmetric. 1H NMR spectra 
for 10d and 3 have visible aromatic multiplets at ca. 7.5 ppm. Spectra for 10c and 10e have 
what appears to be a singlet in that region. This is caused by the absence of the nitrile group 
on the 10c and 10e phenyl ring(s), which break the symmetry of 10d and 3. The cause of this 
single peak is simply due to the use of low field 60 MHz NMR instrument. The weaker magnet 
produces spectra that is not as resolved compared to its more powerful counterpart, which 
can be seen in Figure 15A. The difference in resolution is roughly a factor of 7, which is why 
the quality of the spectrum B is much lower than that of A, with peaks appearing closer 
together and harder to recognise. For example, the extra signal seen in spectrum B is due to 
the coupling being much larger in the 60 MHz bench-top spectrum compared to the 400 MHz 
high-field spectrum. Despite this, the distinct hydrogen region is easily identifiable, allowing 
for the calculation of T1 values. 
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Figure 14. Low-field 1H NMR spectra of compounds 10a - e and 3, with highlighted peaks of 
interest. (marked with ◆ for HA and◆ for HB). 
 
Figure 15. 1H NMR spectra of the same molecule (3) taken on two different NMR instruments. 
Spectrum A has been acquired on a 400 MHz 1H NMR (high field) instrument. Spectrum B has 









4.6 13C{1H} NMR 
13C{1H} NMR spectra were collected for all the compounds analysed. Just as 1H NMR identifies 
hydrogen atoms, 13C{1H} NMR allows the identification of carbon atoms in an organic 
molecule. The reason for 13C NMR to only detect the 13C isotope of carbon, whose natural 
abundance is only 1.1%, is because 12C, the main carbon isotope, is not detectable by NMR 
since it has a spin quantum number of zero and so is not magnetically active. This causes 13C 
NMR to be less sensitive to carbon than its proton counterpart, because only a few 13C nuclei 
present resonate in the NMR magnetic field.93 Similarly to high-field 1H NMR, there were very 
minor differences in peak chemical shift when comparing the 13C{1H} NMR collected data to 
literature. The spectroscopic data collected in this report for 10e is in agreement with that 
previously reported by Doiron et al.83 The chemical shifts for both molecules are very similar, 
varying by 0.5 to 2 ppm. Figure 16 shows a 13C NMR spectrum 3, with reported peaks being 
the same or nearly the same as the peaks reported by Zhang et al.94 
 
Figure 16. 13C NMR spectrum 3 chemical shift δ (ppm): 153.17, 145.98, 144.21, 133.86, 
130.47, 199.15, 133.73, 66.81; collected in methanol-d4 (solvent peak present at the chemical 




4.7 Relaxation times of 10a - e and 3 
The spin-lattice relaxation time (T1) was measured for compounds 10a - e and 3 in order to 
understand how the structural complexity affects the relaxation time. When a 90° radio 
frequency pulse is applied, the longitudinal magnetisation (Mz) will be flipped towards the xy 
plane. The signal detector in NMR is positioned along the xy plane, so the intensity of the 
detected signal will decrease over time due to z-axis relaxation.62 In this report the 
longitudinal (spin-lattice) relaxation, T1, was measured. The relaxation can be represented 
mathematically as: 




The experiment consisted of a series of measurements, each with an increasing time delay 
(τ). In terms of the pulses applied, the T1 pulse sequence utilised begins with a 180° pulse to 
flip Mz to M-z. Prior to a 90° pulse to flip magnetisation into the transverse plane, a time delay 
of length τ is applied. At short τ, the magnetisation signal when flipped into the transverse 
plane will begin from M-z whereas at longer values of τ, relaxation will have occurred so that 
magnetisation will have been partly, or fully, restored in to the Mz direction. A plot of signal 
intensity as a function of τ can then be plotted; a representative T1 plot is shown in Figure 17. 
The T1 value can then be calculated from this. It is important to know the T1 value of each 
compound, as 5-6 T1 are required for the maximum amount of equilibrium magnetisation (Mz) 
to be restored.64 Furthermore, T1 is a measure of how long a hyperpolarized state will persist 




Figure 17. A graph with time (s) on x-axis and integrals on y-axis with a plotted curve used to 
calculate the relaxation time (T1) of molecule 10a. 
T1 values were calculated for 10a - e and 3 in the presence and absence of the SABRE pre-
catalyst, [Ir(IMes)(COD)Cl], and either in an atmosphere of air or vacuum (Table 8). All data 
was collected in d4-MeOH. 
Table 8. T1 values of samples 10a - e and 3 with and without the presence of the catalyst 
  Without the catalyst With the catalyst  
Entry Compound T1 in air / s T1 in vacuum / s T1 in air / s T1 in vacuum / s 
1 10a 6.3 44.8 6.2 41.1 
2 10b 5.8 24.3 4.5 31.6 
3 10c 5.0 17.2 4.3 27.3 
4 10d 5.3 12.0 4.7 25.5 
5 10e 2.8 19.9 4.1 13.5 
6 3 2.8 17.1 3.5 10.1 
 
The relaxation times in air are much smaller due to the presence of oxygen. Dobzhenetskiy et 
al.95 reported that paramagnetic complexes shorten the T1 time. Oxygen is a paramagnetic 
molecule, which means it affects the relaxation times as the unpaired electrons have a high 
magnetic moment, which promotes relaxation and in turn, shortens T1. Therefore, the 
relaxation times for samples in vacuum are 7 to 10 times longer, as there is no oxygen present. 
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The same results were reported by Ashworth et al.,96 who compared the difference in T1 
relaxation times between pyridine samples in air and in vacuum. It was found that T1 
calculated in air to be 4.8 s, and 25.1 s in vacuum – 5 times longer. This reflects the data found 
in this report, where the T1 for compound 10a (entry 1), which is of similar size to pyridine, is 
also around 5 times longer in vacuum. Similarly, to the results recorded for 10a without the 
catalyst, the relaxation time with catalyst and in vacuum is 7 times longer when compared to 
its air counterpart. But upon closer examination of the relaxation values, it was noted that 
the observed T1 values (entries 1-6) in air and in vacuum become shorter between samples 
after the catalyst has been introduced. For molecule 3 (entry 6) the relaxation time in vacuum 
is only 3 times longer in comparison to the T1 time taken in air, which suggests the presence 
of the catalyst decreases the time it takes for the molecule to go back into its original 
relaxation state. During SABRE, rapid polarization transfer is beneficial, but without para-
hydrogen, the catalyst lowers the hyperpolarization by reducing T1. Table 8 shows, the values 
for T1 were becoming shorter, as the size of the molecules increased. Medium-sized molecules 
are known to have slower tumbling rates – which affect the spin-lattice relaxation time - when 
compared to small and large molecules.97 As represented in Figure 18, “free” water – shown 
on the right, with its small molecule size is tumbling too fast in its free state to be effective at 
T1 relaxation. Large molecules, as well as molecules in solid states tumble too slowly, again 
increasing the relaxation time. Medium molecules, located closest to the Larmor frequency 
(fo), have the most optimal tumbling rate, therefore having the shortest T1. fo is the rate of 
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precession of the magnetic moment of the proton around the external magnetic field, which 
is related to the strength of the magnetic field 
Figure 18. A graph representing the difference in T1 relaxation time based on the speed of 
molecular tumbling.  
Molecules closest to the fo give the most efficient T1 relaxation times. Hence, when applying 
this theory to molecules 10a - e and 3, 10a has a longer T1 due to its smaller size when 
compared to molecules 10b - e and 3.  3 has the shortest T1 time due to it being a medium 
sized molecule, which lies closer to fo, therefore having a slower tumbling rate. 
The data which was collected in this report is representative of the data disclosed previously. 
T1 data reported by Weinert98 shows data for propanol-substituted germanium to be 1.2 s, 
and for pure germanium to be 10.6 s, which are similar to the previously reported 10a and 3 
values (entries 1 and 6). The larger molecule has a much smaller spin-lattice relaxation time 
in comparison to the smaller molecule. These values are another example of how a bigger 
molecule has a lower T1 value, and the smaller molecule has a larger T1 value due to the 






Hyperpolarization makes ordinarily impractical measurements become possible, because it 
turns typically weak NMR and MRI responses into strong signals. This section shows how 
compounds 10a, 10b, 10c, 10d and 3 react to hyperpolarization in two different magnetic 
fields; 0.5 G – the earth’s magnetic field and 65 G – the optimal magnetic field strength for 
SABRE hyperpolarization, according to Zeng et al.99 
To understand how/if the complexity of a molecule affects hyperpolarization, a series of 
experiments were performed on molecules 10a - d and 3. All molecules have a triazole ring, 
which should be able to bind to the Ir catalyst through the nitrogen situated in the second 
and fourth position of the ring. The prediction that molecules 10a - d and 3 would 
hyperpolarize was based on the fact that, according to literature, pyridine shows 
enhancements of over 1000.74 The triazole group on molecules 10a - d and 3 is not hindered 
by any of the other groups, and therefore allowed most of the magnetisation to be 
propagated from the para-hydrogen derived hydride ligands through to the triazole protons. 
It has been reported that hyperpolarization using SABRE method is not limited to protons, 
and that hyperpolarization can be transferred to 13C and 15N.100 Literature has shown that 
SABRE hyperpolarization is mostly performed on compounds containing nitrogen. Letrozole 
has been picked as a drug of interest, due to its potential to hyperpolarize and if successful, 
the future implications. It is understood that nitrogen can be hyperpolarized due to the 
existence of a free orbital on the atom, giving 15N a 1/2 spin which allows for the polarization 
transfer. The free orbital on 15N binds to the protons without posing a steric barrier once 
hyperpolarized, and by providing an extended time window for the utilization of the 
hyperpolarized compounds, it can potentially retain their spin alignment for tens of 
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minutes.74,101 This information indicates that molecules containing the nitrile group, such as 
10d and 3 have more than one way of binding with the catalyst, due to the existence of a free 
orbital on the additional N atom which is capable of interacting with a metal centre, as 
reported by R. Mewis et al.102 As such, studying the 15N SABRE polarization could be an area 
of potential future research, but this approach typically requires compounds to be 15N-
labelled. 
 
Figure 19. 1H NMR SABRE spectra for 10a. (1) taken after para-hydrogen addition at 65 G,          
(2) taken after para-hydrogen addition at 0.5 G, (3) thermal spectrum.  
The hydride intermediates observed in spectrum 2 between delta -10 to -20 in Figure 19, 
which are absent from spectrum 1 indicate the successful catalyst activation, which means 
the required J-coupling network was established. The same trend was seen for hyperpolarized 
spectra for compounds 10a - d and 3. In addition to this, the colour of the sample inside the 
tube turned from vibrant yellow to near colourless, as a result of a change in oxidation state 
of the iridium catalyst centre. The addition of para-hydrogen to the complex means that Ir(I) 
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is oxidised to Ir(III), through an oxidative addition process, which explains the change in 
geometry of the catalyst from square planar to octahedral; the complex [Ir(IMes)(L)3(H)2]+ is 
proposed to form where L = 10a - d or 3. Once hydrogenated, the catalyst is fully activated 
and ready to propagate hyperpolarization efficiently to the substrate. The 1H NMR spectra 
acquired following polarization transfer at 0.5 G and 65 G have an enhancement of 3-fold and 
54-fold respectively.  
Figure 20 and 21 show the data collected after SABRE experiment on molecules 10c and 3. 
Similarly to spectrum visible in Figure 19, the hydride intermediates are not visible, as well as 
the colour of the sample inside the tube turned from vibrant yellow to near colourless, 
suggesting a successful catalyst activation. Peak enhancement level (ε) was measured using 
the integration of a hyperpolarized NMR signal, to its unpolarized (thermal) counterpart. 
Figure 20 shows an 8-fold enhancement at 0.5 G, whilst the enhancements almost double to 
17-fold following polarization transfer at 65 G (Figure 20-1). Figure 21-1 and Figure 21-2 
shows spectra of hyperpolarized 3 with a peak enhancement of 6-fold and 7-fold respectively, 

















Figure 20. 1H NMR SABRE spectra for 10c. (1) taken after para-hydrogen addition at 65 G,          







Figure 21.  1H NMR SABRE spectra for 3. (1) taken after para-hydrogen addition at 65 G, (2) 
taken after para-hydrogen addition at 0.5 G, (3) thermal spectrum. 
As seen in Figures 19-21, hyperpolarization is evident, shown through the presence of 
enhanced emission signals at 7.96 ppm. This observation alone shows that the compounds 
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have successfully hyperpolarized. Table 9 shows the peak enhancement for each tested 
molecule.  
Table 9. Data showing the enhancements of a HB peak in different magnetic fields 
 
The magnitudes acquired from the data are lower than expected (Table 9), especially when 
compared to molecules like pyridine. In the limited data available in literature for molecules 
10a - d and 3, it is reported that the peak enhancement is comparable to the data collected 
in this report. Hermkens et. al. 101 report a peak enhancement of 50-fold for molecule 10b 
(entry 2). The enhancement levels cannot be fully compared due to the equipment limitations 
encountered during this study. The main differences were the use of different magnetic field 
strength, as well as a lower percentage of atmospheric para-hydrogen. Hermkens used 100% 
para-hydrogen, which is why their reported data is a factor of 3 larger than the data reported 
in this study. Therefore, a stronger enhancement of molecules could be achieved in this study 
by using a higher percentage of para-hydrogens, which would increase the acquired peak 
enhancement data by a factor of 3, as well as increasing the pressure of para-hydrogen inside 
the tube from 3 bar to 5 bar. As reported by Rayner et al.,96 increasing the para-hydrogen 
  Peak enhancement (ε) at the magnetic fields 
indicated 
Entry Compound 0.5 G 65 G 
1 10a -6 -54 
2 10b -3 -20 
3 10c -8 -17 
4 10d -0.05 -9 
5 3 -6 -7 
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pressure from 3 to 5.5 bar can boost the value of hyperpolarization from 22% to 41% for a 
molecule. 
 Rayner et al.96 also reported that the locations of protons on the ring have a great effect on 
effective SABRE transfer, and therefore hyperpolarization levels, due to potential isolation 
from the hydride ligands of the catalyst. It was concluded that most desirable molecular 
architecture for efficient magnetisation transfer via SABRE is placing a proton next to a 
nitrogen. Since all N-binding sites on compounds 10a - d and 3 are the same, it was reasonable 
to assume they should all have the same or similar polarization levels. The experiments 
proved otherwise, with the peak enhancements mostly decreasing when moving onto the 
next molecule with a higher molecular mass. 3 (entry 5) has the peak enhancement of -7, 
which suggests that the molecule has been polarized successfully, but the enhancement is 
not very high compared to other entries. Peak enhancement measurements were repeated 
three times in every magnetic field and only the highest reading has been recorded, as 
sometimes the catalyst took longer to activate. The poor performance of 3 under SABRE must 
be a consequence of low T1 values, when compared to 10a (entry 1) with high polarization 
level and a long relaxation time. This trend is be visible when comparing T1 data between 
molecules in Table 8. The relaxation times slowly decrease with the added complexity of the 
molecule, which reflects the decrease in hyperpolarization level in Table 9. The theory, which 
was assumed prior to undertaking the experiment, appears to be correct. Compound 10e has 
not been used in SABRE hyperpolarization due to limited access to the laboratory and the 
para-hydrogen generator. If given the chance, a SABRE hyperpolarization would be carried 
out on compound 10e to show how the size of a molecule affects the peak enhancement, and 




To conclude, the carried-out work was a pilot study showing molecule 3 can be 
hyperpolarized, as well as how the size of a molecule affects the peak enhancement. The data, 
which was collected during hyperpolarization, shows there is some correlation between the 
size of the molecule, or the functional groups attached, and the peak enhancement (ε). The 
size and functional groups do affect the chemical shift during 1H NMR analysis, and the data 
suggests that the same can be said when SABRE hyperpolarization is being carried out. 10a 
produced the largest enhancement of -54 at 65 G, probably due to the similarity to pyridine, 
but the enhancements were not as high as expected. However, the main goal of this report 
was to simply demonstrate that the clinically approved drug letrozole could be hyperpolarized 
via SABRE, to obtain a hyperpolarized 1H NMR spectra. Data seen in Table 9 shows that this 
aim has been accomplished, with a ε of 7-fold when a 65 G magnetic field was utilised for 
polarization transfer. For this report, all of the molecules were dissolved in methanol-d4, as it 
was reported to have the best polarization transfer magnetic field strength.98 Upon the 
evaluation of the literature, this work would have undoubtedly benefited from better 
optimisation of the systems investigated. According to Zeng et al.,99 temperature has an effect 
on the peak enhancement for SABRE hyperpolarization. The ‘shake and analyse’ technique 
used in this report gave a potential variance, further increasing the inconsistency of data 
collection. If the methods were completely unsuccessful, there would be no observable 
hyperpolarization entirely, so even these non-fully optimised systems show the SABRE 
hyperpolarization method was successful in that the molecules investigated were polarized. 
The research contained here has again proven that the hyperpolarization technique, SABRE, 
can be applied to biologically relevant compounds. This paves the way for future 
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opportunities that might be focused around studying the biological activity of 3, coupled with 
SABRE hyperpolarization towards, for example, MRI applications.  
6. Future Work 
The aim of this report was to revolutionize clinical diagnosis of breast cancer, in terms of 
utilising the hyperpolarization technique. Proof of concept data has been obtained as it has 
been proven that letrozole can be hyperpolarized. The experimental work carried out in this 
report has to be optimised before final conclusions can be drawn. Variables, such as the 
optimisation of the magnetic field for polarization transfer, para-hydrogen pressure, and 
para-hydrogen mole fraction have to be adjusted to show the best conditions for letrozole 
hyperpolarization. In future work, it would be beneficial to find out how different solvents 
affect the hyperpolarization of letrozole and its derivatives. Methanol-d4 was chosen as the 
first test solvent based on the literature, but it is reported by Zeng et al.,99 that it is highly 
toxic, therefore making it unsuitable for study in vivo. Therefore, solvents like ethanol and 
DMSO, which have lower toxicity and are suitable for intravenous injection (DMSO is often 
used as a drug vehicle in medical research),99 would be the next step in assessing letrozole’s 
use as cancer tracing agent. It was also found, that in SABRE, the polarization efficiency 
depends not only on the magnetic field, but also on the concentration of the substrate. 
Letrozole is utilised at a dosage of 2.5 mg daily. The mass used for this research was 3.4 mg. 
Therefore, it would be advised to run SABRE experiments using the daily dosage. This would 
be advantageous, in terms of collating evidence, to validate whether or not the drug could 
act as a tracing agent, as well as a medication. In terms of the hyperpolarization itself, it would 
be prudent to broaden the knowledge of the topic around the size and complexity of the 
molecule and the affects it has on the hyperpolarization and peak enhancement. Finally, in 
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terms of the biological view, it would be advisable to see how hyperpolarization affects drugs 
which are inside living cells. It is widely understood how the MRI instruments work in 
hospitals, to create images based on the alignment of protons in the body, and how different 
tissues create different images. So, it would be worthwhile to add a drug which can be 1H 
hyperpolarized and test whether it will be visible under MRI conditions, especially against a 
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1,2,4-Triazole (10a)  
 
 










A2 - 1H NMR spectrum 10a collected in methanol-d4 (solvent peaks present at the chemical 







A2a - 13C NMR spectrum 10a collected in methanol-d4 (solvent peak present at the chemical 































A4 - 1H NMR spectrum 10b collected in methanol-d4 (solvent peaks present at the chemical 













A4a- 13C NMR spectrum 10b collected in methanol-d4 (solvent peak present at the chemical 










A6 - GC-MS spectrum of 10c with visible molecular ion and base peaks as well as the 




















































A7 - 1H NMR spectrum 10c collected in methanol-d4 (solvent peaks present at the chemical 
shifts δ 4.78ppm and 3.31ppm) 
 
 
A7a - 13C NMR spectrum 10a collected in methanol-d4 (solvent peak present at the chemical 













A8 - IR spectrum of 10d 
 
A9 - GC-MS spectrum of 10d with visible molecular ion and base peaks as well as the 















A10 - 1H NMR spectrum 10d collected in methanol-d4 (solvent peaks present at the chemical 
shifts δ 4.78ppm and 3.31ppm) 
 
 
A10a - 13C NMR spectrum 10a collected in methanol-d4 (solvent peak present at the 















A11 IR spectrum of 10e 
 
A12- GC-MS spectrum of 10e with visible molecular ion and base peaks as well as the 














A13- 1H NMR spectrum 10b collected in chloroforml-d4 (solvent peaks present at the 
chemical shifts δ 7.26ppm and water peak at the chemical shifts δ 1.6ppm) 
 
 
A13a - 13C NMR spectrum 10a collected in methanol-d4 (solvent peak present at the chemical 







4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile (Letrozole, 3) 
 
 
A14 - IR spectrum of 3 
 
A15 - GC-MS spectrum of 3 with visible molecular ion and base peaks as well as the 














































A16 - 1H NMR spectrum 3 collected in methanol-d4 (solvent peaks present at the chemical 
shifts δ 4.78ppm and 3.31ppm) 
 
 
A16a - 13C NMR spectrum 3 collected in methanol-d4 (solvent peak present at the chemical 
shift δ 49.15 ppm) 
 
 
 
 
